EBMT 2025 Highlight: Comparing Orca-T and PTCy – Insights From the Phase 1b Orca-T and Registry-Based PTCy Patients

Summary for Physicians: Phase 1b ORCA-T and Registry-Based Patients Who Are PTCy Comparison at EBMT (European Society for Blood and Marrow Transplantation) 2025

At EBMT 2025, an update was presented on the Phase 1b ORCA-T trial and its comparison with registry-based patients who are PTCy in a retrospective study:

• Study design: This observational study compared outcomes between patients treated with ORCA-T (from the phase 1b trial) and those receiving PTCy-based regimens (from a patient registry).
• Key outcomes: The analysis showed that ORCA-T treatment was associated with improved outcomes in response rates and progression-free survival compared with the PTCy-based regimen. The safety profile of ORCA-T was also favorable, with manageable adverse events.

The study suggests that ORCA-T may offer better clinical outcomes than standard PTCy-based therapies in this patient population.

Nelli Bejanyan reports consulting or advisory role for CareDx, Medexus Pharmaceuticals, Orca Biosystems, AlloVir, TScan Therapeutics, and Pfizer; and research funding from CRISPR Therapeutics. Everett Meyer reports sponsored research from Orca Biosciences, Kyverna; and a scientific advisor role and equity holder for GigaMune, Indee, TRACT, Jura Biosciences.Caspian Oliai reports no relevant disclosures (investigator on the Orca T trial funded by Orca Biosciences). Arpita P. Gandhi reports roles with OncLive, MJH Life Sciences, OrcaBio (research), CareDx (Advisory Board). Amandeep Salhotra reports received funding from Rigel, Bristol Myers Squibb and Orca Biosciences; and speakers bureau for Incyte and Sanofi.